ReviewInfectious diseases and therapy2026
Understanding the Epidemiology and Contributing Factors of Post-COVID-19 Pertussis Outbreaks: A Narrative Review.
Review in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Article
- Clinical features, disease severity, and outcomes of pertussis in hospitalized children: A retrospective study from Serbia.PloS one · 2026Article
- Post-marketing safety surveillance of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine: a disproportionality analysis of the vaccine adverse event reporting system (2015-2025).Frontiers in cellular and infection microbiology · 2026Article
- Revisiting Whooping Cough: Global Drivers and Implications of Pertussis Resurgence in the Acellular Vaccine Era.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pertussis or whooping cough, caused by the bacteria Bordetella pertussis, is a highly contagious respiratory disease. Over the past century, whole-cell pertussis (wP) and acellular pertussis (aP) vaccines were developed and widely adopted, leading to a substantial reduction in the number of pertussis cases. Currently, various strategies are employed to protect different segments of the population, including primary immunization, toddler and school-age boosters, adult boosters, and vaccination in pregnancy (ViP). Nonetheless, pertussis remains a global health challenge with periodic outbreaks occurring every 2-5 years. The non-pharmacological measures implemented during the COVID-19 pandemic resulted in a drastic reduction in the circulation of B. pertussis. However, post-pandemic, there has been a resurgence in pertussis cases. This review aims to explore the post-pandemic global pertussis outbreaks and identify underlying trends to gain insights into the potential contributing factors. As of June 2025, pertussis outbreaks with diverse epidemiological patterns have been reported in at least 42 countries, including 30 aP and 12 wP vaccine-using countries. Some common observations among these countries include low infant immunization rates and an absence of vaccination programs for specific populations such as school-aged children, adults, and pregnant individuals. Additionally, in countries with extensive immunization schedules and high vaccination uptake, outbreaks have occurred in regions with low vaccination coverage rates (VCRs). Multiple interrelated factors may have contributed to the post-pandemic pertussis outbreaks, such as the cyclic epidemiology of pertussis, low VCR, waning vaccine-derived immunity, low uptake of boosters, and lack of lifelong protection through regular boosters. To effectively mitigate the incidence of pertussis outbreaks, it is crucial to administer regular booster vaccinations throughout an individual's lifetime, with particular emphasis on at-risk populations and pregnant individuals. A Graphical Abstract is available for this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.